KLRC1 and COVID-19: On the other hand, other experimental evidence demonstrated that NKG2A is downregulated in COVID-19 patients and that this downregulation is counterbalanced by the upregulation of NKG2C, the activating counterpart of NKG2A, especially in severe ones.